Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and <i>O</i>-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling

Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and <i>O</i>-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling

Tramadol is a &#956;-opioid receptor agonist and a monoamine reuptake inhibitor. <i>O</i>-desmethyltramadol (M1), the major active metabolite of tramadol, is produced by CYP2D6. A physiologically-based pharmacokinetic model was developed to predict changes in time-concentration profi...

Full description

Bibliographic Details
Main Authors: Hyeon-Cheol Jeong, Soo Hyeon Bae, Jung-Woo Bae, Sooyeun Lee, Anhye Kim, Yoojeong Jang, Kwang-Hee Shin
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Pharmaceutics
Subjects:
cyp2d6
<i>o</i>-desmethyltramadol
pharmacokinetics
physiologically-based pharmacokinetics
tramadol
Online Access:https://www.mdpi.com/1999-4923/11/11/618

Internet

https://www.mdpi.com/1999-4923/11/11/618

Similar Items